CJC-1295 (No DAC)Also known as: CJC-1295 without DAC, Growth Hormone Releasing Hormone (GHRH) analog

Mechanism of Action

CJC-1295 without DAC acts as a synthetic analog of growth hormone releasing hormone (GHRH). It binds to GHRH receptors in the anterior pituitary gland, stimulating pulsatile release of endogenous growth hormone. Unlike the DAC (Drug Affinity Complex) variant, it has a shorter half-life and does not exhibit prolonged receptor binding, allowing for controlled and physiologic patterns of GH secretion and reduced risk of receptor desensitization.

Reported Research Benefits

Primarily used in preclinical and laboratory research to study natural stimulatory effects on growth hormone secretion, muscle growth, fat metabolism, tissue regeneration, and sleep regulation. Also utilized in combination with growth hormone secretagogues like Ipamorelin to synergistically enhance GH release.

Dosing Protocol & Reconstitution

Supplied as a 10 mg lyophilized powder, reconstituted with bacteriostatic water prior to subcutaneous injection. Research dosing is often pulsed and carefully controlled due to its short half-life, allowing investigators to modulate frequency and timing to study GH pulsatility and associated metabolic effects. Specific dosing protocols should be designed for each experimental setup.

Research Notes

Offers a short-acting profile favorable for controlled experimental modulation of GH secretion without prolonged receptor occupancy typical of DAC-containing analogs. Demonstrated over 99% purity in third-party batch testing. Used to model anabolic, regenerative, and metabolic responses in preclinical research. Often studied in combination with other peptides for synergistic effects on hormonal axes.

Research Summary

CJC-1295 without DAC (also called Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH release from the pituitary. It has a short half-life (~30 minutes), maintaining a more physiological GH secretion pattern. Clinical studies show it increases IGF-1 and promotes fat loss, lean mass, and recovery when combined with a GHRP.

Side Effects & Safety

Water retention, joint discomfort, numbness/tingling (carpal tunnel-like symptoms), increased appetite, and transient fatigue are common at higher doses. Risk of insulin resistance with prolonged elevated GH/IGF-1. Pituitary desensitization possible with chronic use.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: D-Ala-His-D-2-Nal-Ala-Trp-D-Phe-Lys-Val-Lys-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Ile-NH2
Molecular Weight: 4761.7 g/mol
CAS Number: 863288-34-0

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+GHRH+growth+hormone